Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance

Journal of Cardiovascular Magnetic Resonance

Volumn 15, Issue 1, 2013, Pages

  Dellinger, Anthony ^a,b   Olson, John ^c   Link, Kerry ^c   Vance, Stephen ^b   Sandros, Marinella G ^b   Yang, Jijin ^d   Zhou, Zhiguo ^a   Kepley, Christopher L ^b  

^a LUNA INNOVATIONS INC   (United States)

^b Joint School of Nanoscience and Nanoengineering   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d CARL ZEISS SMT AG   (Germany)

Author keywords

Atherosclerosis; Cd36; Contrast agent; Macrophage; Magnetic resonance imaging; Metallofullerenes

Indexed keywords

CD36 ANTIGEN; FULLERENE DERIVATIVE; GADOLINIUM; LIPOSOME; METALLOFULLERENE DERIVATIVE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; CONTRAST MEDIUM; DIAGNOSTIC AGENT; LIGAND; ORGANOMETALLIC COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; FEMALE; FOAM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPID BILAYER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TOXICITY TESTING; WESTERN BLOTTING; WILD TYPE; ANIMAL; AORTA; AORTA DISEASE; ATHEROSCLEROSIS; C57BL MOUSE; CELL STRAIN U937; DISEASE MODEL; GENETICS; METABOLISM; MOUSE MUTANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; TIME;

ANIMALS; ANTIGENS, CD36; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOTTING, WESTERN; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FOAM CELLS; FULLERENES; HUMANS; LIGANDS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, SCANNING; ORGANOMETALLIC COMPOUNDS; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; TIME FACTORS; U937 CELLS;

MLCS; MLOWN;

EID: 84872188334     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-15-7     Document Type: Article

References (53)

1. Buxton DB, Antman M, Danthi N, et al. Report of the national heart, lung, and blood institute working group on the translation of cardiovascular molecular imaging. Circulation. 2011; 123(19):2157-63.
2. Underhill HR, Hatsukami TS, Fayad ZA, Fuster V, Yuan C. MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol. 2010; 7(3):165-73.
3. Stevenson S, Fowler PW, Heine T, et al. A stable non-classical metallofullerene family. Nature. 2000; 408(6811):427-8.
4. MacFarland DK, Walker KL, Lenk RP, et al. Hydrochalarones: A novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J Med Chem. 2008; 51(13):3681-3.
5. Podrez EA, Poliakov E, Shen Z, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002; 277(41):38503-16.
6. Nagaraja TN, Croxen RL, Panda S, et al. Application of arsenazo III in the preparation and characterization of an albumin-linked, gadoliniumbased macromolecular magnetic resonance contrast agent. J Neurosci Methods. 2006; 157(2):238-45.
7. Zhou Z, Lenk RP, Dellinger A, Wilson SR, Sadler R, Kepley CL. Liposomal formulation of amphiphilic fullerene antioxidants. Bioconjug Chem. 2010; 21(9):1656-61.
8. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7.
9. Kuzuya M, Yamada K, Hayashi T, et al. Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density lipoprotein. Biochim Biophys Acta. 1992; 1123(3):334-41.
10. Koopman R, Schaart G, Hesselink MK. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol. 2001; 116(1):63-8.
11. Norton SK, Dellinger A, Zhou Z, et al. A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release. Clin Transl Sci. 2010; 3(4):158-69.
12. Ehrich M, Van Tassell R, Li Y, Zhou Z, Kepley CL. Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro. Toxicol In Vitro. 2011; 25(1):301-7.
13. Tkaczyk C, Metcalfe DD, Gilfillan AM. Determination of protein phosphorylation in Fc varepsilon RI-Activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J Immunol Methods. 2002; 268(2):239-43.
14. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm Des. 2008; 14(4):338-51.
15. Rosenfeld ME, Averill MM, Bennett BJ, Schwartz SM. Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets. 2008; 9(3):210-6.
16. Wiant D, Atwood TF, Olson J, et al. Gamma knife radiosurgery treatment planning for small animals using high-resolution 7 T micro-magnetic resonance imaging. Radiat Res. 2009; 172(5):625-31.
17. Alsaid H, De SG, Bourdillon MC, et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of ApoE-/- mice: A pilot study. Invest Radiol. 2009; 44(33):151.
18. Moukdar F, Robidoux J, Lyght O, Pi J, Daniel KW, Collins S. Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice. J Lipid Res. 2009; 50(1):59-70.
19. Anne-Marie I, Candice H, Han-Zhang X, et al. Immunohistochemical detection of human basophils in late-phase skin reactions. J Allergy ClinImmunol. 1997; 101(3):354-62.
20. Kepley CL, Craig SS, Schwartz LB. Identification and partial characterization of a unique marker for human basophils. J Immunol. 1995; 154(12):6548-55.
21. Nicholson AC, Han J, Febbraio M, Silversterin RL, Hajjar DP. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann NY Acad Sci. 2001; 947:224-8.
22. Brown MS, Basu SK, Falck JR, Ho YK, Goldstein JL. The scavenger cell pathway for lipoprotein degradation specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J Supramol Struct. 1980; 13(1):67-81.
23. Collins RF, Touret N, Kuwata H, Tandon NN, Grinstein S, Trimble WS. Uptake of oxidized low density lipoprotein by CD36 occurs by an actin-dependent pathway distinct from macropinocytosis. J Biol Chem. 2009; 284(44):30288-97.
24. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006; 4(3):211-21.
25. Partovi S, Loebe M, Aschwanden M, et al. Contrast-enhanced ultrasound for assessing carotid atherosclerotic plaque lesions. AJR Am J Roentgenol. 2012; 198(1):W13-W19.
26. Voros S, Rinehart S, Qian Z, et al. Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-Analysis. JACC Cardiovasc Imaging. 2011; 4(5):537-48.
27. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA. 2007; 104(3):961-6.
28. Collot-Teixeira S, Martin J, rmott-Roe C, Poston R, McGregor JL: CD36 And macrophages in atherosclerosis. Cardiovasc Res. 2007; 75(3):468-77.
29. Kahn E, Vejux A, Menetrier F, et al. Analysis of CD36 expression on human monocytic cells and atherosclerotic tissue sections with quantum dots: investigation by flow cytometry and spectral imaging microscopy. Anal Quant Cytol Histol. 2006; 28(1):14-26.
30. Nergiz-Unal R, Rademakers T, Cosemans JM, Heemskerk JW. CD36 As a multiple-ligand signaling receptor in atherothrombosis. Cardiovasc Hematol Agents Med Chem. 2011; 9(1):42-55.
31. Lipinski MJ, Amirbekian V, Frias JC, et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med. 2006; 56(3):601-10.
32. Ouimet T, Lancelot E, Hyafil F, et al. Molecular and cellular targets of the MRI contrast agent p947 for atherosclerosis imaging. Mol Pharm. 2012; 9(4):850-61.
33. Lipinski MJ, Frias JC, Amirbekian V, et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging. 2009; 2(5):637-47.
34. Uchida M, Kosuge H, Terashima M, et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano. 2011; 5(4):2493-502.
35. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007; 13(5):636-41.
36. Davies JR, Rudd JH, Weissberg PL, Narula J: Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol. 2006; 47(8 Suppl):C57-C68.
37. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006; 114(14):1504-11.
38. Nahrendorf M, Sosnovik DE, Weissleder R. MR-optical imaging of cardiovascular molecular targets. Basic Res Cardiol. 2008; 103(2):87-94.
39. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18 F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105(23):2708-11.
40. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003; 107(19):2453-8.
41. Canet-Soulas E, Letourneur D. Biomarkers of atherosclerosis and the potential of MRI for the diagnosis of vulnerable plaque. MAGMA. 2007; 20(3):129-42.
42. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 Is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993; 268(16):11811-6.
43. Fatouros PP, Corwin FD, Chen ZJ, et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology. 2006; 240(3):756-64.
44. Kolosnjaj J, Szwarc H, Moussa F. Toxicity studies of fullerenes and derivatives. Adv Exp Med Biol. 2007; 620:168-80.
45. Norton SK, Wijesinghe DS, Dellinger A, et al. Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma. J Allergy Clin Immunol. 2012; 130(3):761-9.
46. Fillmore HL, Shultz MD, Henderson SC, et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine (Lond). 2011; 6(3):449-58.
47. Shu C, Corwin FD, Zhang J, et al. Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity. Bioconjug Chem. 2009; 20(6):1186-93.
48. Zhang J, Fatouros PP, Shu C, et al. High relaxivity trimetallic nitride (Gd(3) N) metallofullerene MRI contrast agents with optimized functionality. Bioconjug Chem. 2010; 21(4):610.
49. Aschberger K, Johnston HJ, Stone V, et al. Review of fullerene toxicity and exposure -Appraisal of a human health risk assessment, based on open literature. Regul Toxicol Pharmacol. 2010; 58(3):455-73.
50. Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology. 2006; 225(1):48-54.
51. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005; 5(12):2578-85.
52. Quick KL, Ali SS, Arch R, Xiong C, Wozniak D, Dugan LL. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol Aging. 2008; 29(1):117-28.
53. Baati T, Bourasset F, Gharbi N, et al. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. Biomaterials. 2012; 33(19):4936-46.